Biochemical and clinical biomarkers in adult SMA 3–4 patients treated with nusinersen for 22 months

OBJECTIVE: To investigate biomarkers of disease progression in cerebrospinal fluid (CSF) and serum in adult patients with spinal muscular atrophy (SMA). Furthermore, we assess the clinical response to nusinersen treatment in adults with SMA over a longer follow‐up period than the previously reported...

Descripción completa

Detalles Bibliográficos
Autores principales: De Wel, Bram, De Schaepdryver, Maxim, Poesen, Koen, Claeys, Kristl G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9380134/
https://www.ncbi.nlm.nih.gov/pubmed/35833245
http://dx.doi.org/10.1002/acn3.51625

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9380134/
https://www.ncbi.nlm.nih.gov/pubmed/35833245
http://dx.doi.org/10.1002/acn3.51625

Ejemplares similares